Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Sponsor: Tobira Therapeutics, Inc.
Terminated
This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.
Other terminated trials from Tobira Therapeutics, Inc.
More terminations from Tobira Therapeutics, Inc.
Other Liver Cirrhosis trials with similar outcome
A PHASE2 clinical study on Liver Cirrhosis and Non-alcoholic Fatty Liver Disease, this trial is terminated or withdrawn. The trial is conducted by Tobira Therapeutics, Inc. and has accumulated 18 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Mar 2022 [monthly]
Terminated PHASE2
▶ Show 13 earlier versions
-
Feb 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Enrolling By Invitation → Terminated
-
Jan 2021 — Feb 2021 [monthly]
Enrolling By Invitation PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Enrolling By Invitation PHASE2
-
Jul 2020 — Sep 2020 [monthly]
Enrolling By Invitation PHASE2
-
Apr 2020 — Jul 2020 [monthly]
Enrolling By Invitation PHASE2
-
Oct 2019 — Apr 2020 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Enrolling By Invitation PHASE2
-
Dec 2017 — Feb 2018 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2017 — Dec 2017 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
May 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Feb 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tobira Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Adelaide, Australia , Angers, France , Bakersfield, United States , Baltimore, United States , Barcelona, Spain , Bastrop, United States , Bedford Park, Australia , Berlin, Germany , Bologna, Italy and 57 more locations